提取Moringa oleifera作为阿尔茨海默氏症疾病的战略植物疗法
Rita Carrotta1, Silvia Vilasi1, Maria Assunta Costa1
1Institute of Biophysics, National Research Council Palermo Italy.
Food science & nutrition
|March 27, 2025
概括
富含多的Moringa oleifera叶片提取物有效地抑制了粉样β聚合,这是阿尔茨海默病的关键因素. 这些植物提取物还可以保护细胞免受损伤,并减少有毒的产生.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 植物化学 植物化学
背景情况:
- 植物提取物,特别是富含多的植物提取物,对神经保护有很大的希望.
- 聚醇作为抗氧化剂,并抑制粉样蛋白聚合物的形成,这与神经退行性疾病有关.
研究的目的:
- 描述Moringa oleifera (MO) 水性提取物中的多含量和抗氧化能力.
- 评估MO提取物对阿米洛伊德β-1-42 (Aβ1-42) 聚合的抑制作用.
- 评估MO提取物在阿尔茨海默氏病细胞模型上的神经保护作用.
主要方法:
- 使用UHPLC-HESI-MS.对MO叶的水性提取物进行了分析,以检测多含量和抗氧化活性.
- 使用生物物理特征的方法研究了Aβ1-42聚合的抑制.
- 使用阿尔茨海默病细胞模型 (SH-SY5Y细胞) 来测试MO提取物对抗糖甲酸诱导毒性的神经保护作用.
主要成果:
- 发现MO水性提取物富含多,具有显著的抗氧化剂和自由基清除能力.
- 莫提取物显示出对Aβ1-42粉样蛋白聚合过程的强烈抑制.
- 在阿尔茨海默氏病细胞模型中,MO提取物预处理改善了细胞活力,减少了线粒体反应性氧物种,并降低了Aβ1-42的产生.
结论:
- 莫林加叶提取物具有显著的神经保护性质.
- 观察到的神经保护归因于多醇含量,抗氧化活性和粉样蛋白聚合的抑制.
- 莫提取物代表了阿尔茨海默病的潜在治疗策略.
更多相关视频
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
2.2K
05:54Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials
Published on: May 10, 2024
2.4K
相关概念视频
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:30Dementia
696
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
696
01:29Alzheimer Disease l: Introduction
38
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
38
01:23Alzheimer Disease ll: Pathophysiology
44
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
44
01:22Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35